Yinchenhao Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a standardized multi-herb extract prepared from Artemisia capillaris Thunb., Gardenia jasminoides Ellis, and Rheum palmatum L. The product is manufactured in two designations: YCH-VG-101, a spray-dried oral and premix grade, and YCH-VG-101M, a micronized injection and solution processing grade with laser-diffraction D90 of ≤45 µm. The extraction route uses low-temperature decoction or hydroethanolic solvent, clarification, rising-film evaporation at 60–70°C under vacuum, and spray drying at inlet 160–180°C and outlet 80–90°C. Emodin-related anthraquinones are weakly acidic, and extraction efficiency is therefore pH-dependent; strongly acidic conditions reduce anthraquinone yield. The spray-dried powder has a glass transition range near 60–70°C, requiring outlet temperature control to prevent chamber-wall sticking. Spray dryer feed solids are typically 20–30% w/w; lower solids reduce particle density and raise drying costs, while higher solids increase viscosity and nozzle clogging. The micronized grade is air-jet milled under nitrogen to limit thermal degradation and moisture uptake. The resulting powder is yellow-brown to dark brown, with a characteristic bitter taste, and is intended solely for veterinary pharmaceutical manufacture.

Two specification tiers are applied to the oral/premix and injection/solution grades. For YCH-VG-101, marker content is scoparone ≥0.5% w/w, geniposide ≥0.8% w/w, and total anthraquinones expressed as emodin ≥0.4% w/w by HPLC. YCH-VG-101M retains the same marker profile but adds clarified-solution, low-endotoxin, and sub-visible particle controls. Loss on drying is ≤5.0% for the oral grade and ≤4.0% for the micronized grade. Moisture above 5.0% has been associated with poor die filling and reduced content uniformity in rotary tablet presses and tamping-pin encapsulation machines. Bulk density of the spray-dried grade is typically 0.35–0.55 g/mL; tapped density by USP <616> gives a Hausner ratio of 1.25–1.45.

Because field-grown botanical raw materials vary with soil mineral content, harvest date, and post-harvest drying temperature, chromatographic release is not limited to a single marker. The HPLC method uses an octadecylsilyl column of 250 × 4.6 mm, 5 µm particle size, with a gradient of acetonitrile and 0.1% phosphoric acid. UV detection is set at 238 nm for geniposide and 254 nm for anthraquinones. System suitability requires a tailing factor ≤2.0 and theoretical plates ≥2,000 for the geniposide peak. Pesticide residue testing follows USP <561>; residual solvents follow USP <467>. Aflatoxins B1, B2, G1, and G2 are limited to <5 µg/kg total. Multi-marker similarity indices are computed against a reference chromatogram, with a typical acceptance criterion of ≥0.95 for commercial batch release. The specification exists to separate veterinary pharmaceutical use from feed additive or human botanical extract use.

How Does a Veterinary-Grade Multi-Herb API Differ from Ground Botanical Powder?

Ground botanical powder retains the full plant matrix, including cellulose, lignin, and the native microbial flora of the dried herb; marker content can vary by 20–50% between harvests. The extracted API is concentrated and standardized, allowing a consistent three-marker profile across batches. Feed-grade botanical powders may be acceptable for oral feed use but are not manufactured under pharmaceutical controls for injection, solution, or capsule use. The veterinary API is also distinct from single-herb Artemisia capillaris extract, which lacks the geniposide and anthraquinone markers contributed by Gardenia and Rheum and therefore does not reproduce the same chromatographic fingerprint.

The comparison is not limited to marker content. In process terms, feed-grade powders create additional filtration load when solutions are prepared, and their residual pesticide and heavy-metal profiles are often not controlled to the same analytical frequency. This difference becomes critical when the API is incorporated into sterile injectable preparations.

For tablet compression, YCH-VG-101 is not suitable as a direct-compression base at extract loading above 30% w/w unless tablet weight is ≥400 mg and turret speed is below 30 rpm. The spray-dried powder has a Hausner ratio above 1.25, so die fill becomes erratic at higher turret speeds. Wet granulation is preferred for higher loadings; a high-shear granulator with impeller tip speed of 2–5 m/s and chopper speed of 1,000–2,000 rpm is used with microcrystalline cellulose and povidone K30. The wet mass is dried at 55–60°C to a final moisture of 2.0–4.0%. Drying below 2.0% has caused edge wear and capping on rotary tablet presses, while moisture above 4.0% has caused sticking on punch faces. Tablet hardness is typically held at 6–10 kp with friability below 1.0%; disintegration is checked under USP <701> for uncoated oral tablets. Content uniformity is evaluated under USP <905>. For capsules, a tamping-pin machine requires 0.5% w/w magnesium stearate and 0.5–1.0% w/w colloidal silicon dioxide; processing rooms above 60% RH increase fill-weight variability. Powder bulk density usually accommodates size 0 or 1 capsules when fill weights are 300–500 mg; lower-density blends may require size 00 or preliminary roller compaction. Dissolution method development should follow USP <711> because no compendial monograph sets universal conditions for this multi-herb API.

During premix manufacture, blend uniformity is the critical endpoint rather than compact strength. YCH-VG-101 is first diluted with precipitated silica or calcium carbonate at 1:9 before addition to a double-shaft paddle mixer. A mixing time of 10–15 min at ≥10 kg/tonne inclusion has produced a coefficient of variation below 5%; direct addition of undiluted extract has caused segregation in post-mix conveying. Powders and granules for oral use are packaged in foil-laminate sachets because polyethylene-only film above 60% RH allows moisture ingress and lump formation. For drinking-water solutions, the oral grade is dispersed at 20–30°C with continuous agitation for 15 min, then passed through a 100 µm inline strainer before distribution.

When Injectable and Solution Dosage Forms Require Endotoxin Control

Injectable processing requires the micronized grade YCH-VG-101M with bacterial endotoxins below 0.25 EU/mg and total aerobic microbial count below 100 CFU/g. The powder is dispersed in Water for Injection at 20–40°C and adjusted to pH 6.5–7.5 with dilute sodium hydroxide or hydrochloric acid. Clarification is performed through 0.45 µm PVDF followed by 0.22 µm PES membranes before terminal sterilization at 121°C for 15 min. Precipitation has been observed with phosphate-buffered saline at extract concentrations above 10 mg/mL; alkaline pH above 8.0 has been associated with color darkening and marker loss. Injectable batches should be checked for sub-visible particles under USP <788> and sterility under USP <71>. Published data for this specific configuration is limited, so real-time stability studies are required under veterinary stability guidance for each formulation and target species.

After opening, the packaged product is re-sealed under nitrogen or with silica gel because reabsorbed moisture above 5.0% raises water activity above 0.60 and can promote microbial growth in non-sterile oral grades. Storage of unopened containers is specified at ≤25°C and ≤45% RH. Bulk packs are double polyethylene-lined aluminum foil laminate drums of 10 kg and 25 kg. The API should not be blended with strong oxidizing agents or with high-acid premixes below pH 3.0; compatibility with amine-based additives is limited and should be confirmed before formulation. The anthraquinone fraction supplied by Rheum can be a gastrointestinal irritant in some monogastric species, so dose limits require species-specific tolerance evaluation.

Unlike single-moiety synthetic hepatoprotectants such as silybin, choline chloride, or methionine, Yinchenhao Powder is not assayed as a single active moiety. Its release is based on multi-marker chromatographic fingerprinting and botanical identity under USP <561>. This creates a different regulatory profile for veterinary drug master files, in which batch equivalence must address marker stability, residual solvent and pesticide limits, and similarity indices rather than single-assay potency. The injection/solution grade cannot be replaced by the oral/premix grade without additional purification. Published outcome data in food-producing species remain limited; therefore withdrawal periods and target-species safety are established by the applicant using residue depletion and toxicological studies in the actual formulation.